← Human Trials & Peer-Reviewed Studies
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect
Plain-language guide to PMID 16420565 (2006): clinical trial study of Vasopressin and Desmopressin.
Key Facts
- PMID
- 16420565
- Journal
- Journal of thrombosis and haemostasis : JTH
- Year
- 2006
- Study type
- Clinical Trial
- Authors
- Castaman G et al. (6 authors)
- DOI
- 10.1111/j.1538-7836.2006.01706.x
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Vasopressin and Desmopressin.
To evaluate biological responsiveness to desmopressin, the FVIII/VWF changes during pregnancy and the clinical outcome in pregnancies and deliveries of six primipara with type 2M VWD Vicenza prospectively followed.
Prior to pregnancy, all patients had undergone desmopressin test-infusion to assess biological responsiveness and its possible clinical usefulness.
Why It Was Studied
Type 2M von Willebrand disease (VWD) Vicenza is characterized by the presence of ultra-large von Willebrand factor (VWF) multimers in plasma and very low factor VIII (FVIII)/VWF measurements.
No data on FVIII/VWF changes after desmopressin and during pregnancy in patients with phenotypic VWD Vicenza has been reported.
Who Took Part
The age groups tagged for this paper are adults, women only.
Three women with single (R1205H) and three with double (R1205H and M740I) mutation in the VWF gene were enrolled in the study.
What Was Measured
Type 2M von Willebrand disease (VWD) Vicenza is characterized by the presence of ultra-large von Willebrand factor (VWF) multimers in plasma and very low factor VIII (FVIII)/VWF measurements.
PubMed files the paper under topics including Deamino Arginine Vasopressin, Factor VIII, Genotype, Hemostatics, Phenotype, Point Mutation and Pregnancy Complications, Hematologic.
What This Means in Plain Language
This is a clinical trial of Vasopressin and Desmopressin.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2006 (Journal of thrombosis and haemostasis : JTH), a journal based in England.
More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.
Our Notes on the Compounds
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.